Cancer of Stomach Clinical Trial
Official title:
Phase II Study of NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma
This is a non-randomized pauci-centre, open-label phase II study. The treatment will consist
in a chemotherapy by FOLFOX and nab-paclitaxel following modalities determined in the Brown
University Phase I study.
In neoadjuvant setting : 3 months of treatment
Main criteria of Withdraw of the treatment: in case of tumor progression, non acceptable
toxicity, or patient decision.
Post-operative treatment (for 6 additional cycles) is recommended, but will depend on the
result of the neo-adjuvant treatment and the ability of patients to receive adjuvant
chemotherapy based on tolerance of neo-adjuvant treatment and general post-operative
condition (i.e. adjuvant treatment if no progression during neo-adjuvant chemotherapy, less
than 80% of residual viable tumor compared to initial tumor volume, acceptable tolerance and
post-operative PS 0 - 2). Adjuvant treatment must be initiated within 8 weeks
post-operatively.
This is a non-randomized pauci-centre, open-label phase II study. The treatment will consist
in a chemotherapy by FOLFOX and nab-paclitaxel following modalities determined in the Brown
University Phase I study.
In neoadjuvant setting : 3 months of treatment
Main criteria of Withdraw of the treatment: in case of tumor progression, non acceptable
toxicity, or patient decision.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00164918 -
Role of Routine Nasogastric Decompression After Subtotal Gastrectomy
|
Phase 3 | |
Completed |
NCT00201747 -
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
|
Phase 2 | |
Completed |
NCT05088304 -
GLIM-defined Malnutrition Criteria for Postoperative Outcomes in Patients With Esophagogastric Cancer
|
||
Active, not recruiting |
NCT00164892 -
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial
|
Phase 3 | |
Active, not recruiting |
NCT00165048 -
Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial
|
Phase 3 | |
Recruiting |
NCT05179824 -
Tempus Priority Study: A Pan-tumor Observational Study
|
||
Recruiting |
NCT03129139 -
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03468712 -
Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
|
N/A | |
Recruiting |
NCT03301493 -
Genomic Testing and Resulting Medical Decisions
|
||
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Completed |
NCT01614522 -
A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2
|
Phase 2 | |
Completed |
NCT02374255 -
Improving Goals of Care Discussion in Advanced Cancer Patients
|
N/A | |
Recruiting |
NCT05804331 -
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
|
||
Active, not recruiting |
NCT03775525 -
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04270890 -
Investigation of an Abdominal Compression Device
|
N/A | |
Not yet recruiting |
NCT05041335 -
Wet Heparinized Suction for Abdominal Cancer
|
N/A | |
Completed |
NCT03541629 -
Audit of the Spanish EURECCA Esophagogastric Cancer Registry
|
||
Completed |
NCT03102229 -
Real-time Activity Monitoring to Prevent Admissions During RadioTherapy
|
N/A | |
Not yet recruiting |
NCT05747482 -
Omentectomy vs Omental Preservation in Resectable Cancer
|
N/A | |
Completed |
NCT03719716 -
Early Support in Primary Care for People Starting Treatment for Cancer
|
N/A |